{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:27:01Z","timestamp":1786991221444,"version":"build-2736575974"},"reference-count":78,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jaad.2021.04.081","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T04:42:15Z","timestamp":1619844135000},"page":"1093-1106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Primary cutaneous T-cell lymphomas other than mycosis fungoides and S\u00e9zary syndrome. Part II: Prognosis and management"],"prefix":"10.1016","volume":"85","author":[{"given":"Yuna","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Stoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Pulitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Myskowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.jaad.2021.04.081_bib1","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2011-05-351346","article-title":"EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma","volume":"118","author":"Kempf","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jaad.2021.04.081_bib2","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jaad.2021.04.081_bib3","first-page":"1112","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"134","author":"Willemze","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jaad.2021.04.081_bib4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jaad.2021.04.081_bib5","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/jdv.16065","article-title":"Frequency and prognosis of associated malignancies in 504 patients with lymphomatoid papulosis","volume":"34","author":"Melchers","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2021.04.081_bib6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaad.2015.09.013","article-title":"Lymphomatoid papulosis: treatment response and associated lymphomas in a study of 180 patients","volume":"74","author":"Wieser","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2021.04.081_bib7","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","article-title":"Primary and secondary cutaneous CD30+ lymphoproliterative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment","volume":"95","author":"Bekkenk","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jaad.2021.04.081_bib8","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2230.2008.03024.x","article-title":"Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients","volume":"34","author":"Kunishige","year":"2009","journal-title":"Clin Exp Dermatol"},{"issue":"13","key":"10.1016\/j.jaad.2021.04.081_bib9","first-page":"1158","article-title":"Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders","volume":"23","author":"Kadin","year":"2009","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"10.1016\/j.jaad.2021.04.081_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.hoc.2016.11.006","article-title":"CD30(+) lymphoproliferative disorders of the skin","volume":"31","author":"Sauder","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"10.1016\/j.jaad.2021.04.081_bib11","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0190-9622(96)90442-9","article-title":"Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders","volume":"34","author":"Vonderheid","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.04.081_bib12","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/bjd.13920","article-title":"Recommendations for treatment of lymphomatoid papulosis with methotrexate: a report from the Dutch Cutaneous Lymphoma Group","volume":"173","author":"Bruijn","year":"2015","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.04.081_bib13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/ced.13256","article-title":"First-line treatment in lymphomatoid papulosis: a retrospective multicentre study","volume":"43","author":"Fern\u00e1ndez-de-Misa","year":"2018","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.04.081_bib14","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/bjd.15801","article-title":"Brentuximab vedotin in CD30 + cutaneous lymphoma: how do we treat, how shall we treat? A review of the literature","volume":"177","author":"Stranzenbach","year":"2017","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2021.04.081_bib15","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jamadermatol.2017.3593","article-title":"Brentuximab vedotin for patients with refractory lymphomatoid papulosis","volume":"153","author":"Lewis","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"19","key":"10.1016\/j.jaad.2021.04.081_bib16","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jaad.2021.04.081_bib17","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/cup.12937","article-title":"Primary cutaneous anaplastic large cell lymphoma","volume":"44","author":"Brown","year":"2017","journal-title":"J Cutan Pathol"},{"issue":"5","key":"10.1016\/j.jaad.2021.04.081_bib18","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ijrobp.2017.08.010","article-title":"Recommendations for the optimal radiation dose in patients with primary cutaneous anaplastic large cell lymphoma: a report of the Dutch cutaneous lymphoma group","volume":"99","author":"Melchers","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.jaad.2021.04.081_bib19","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0190-9622(03)02484-8","article-title":"CD30(+) cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma","volume":"49","author":"Liu","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.04.081_bib20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1001\/archdermatol.2009.74","article-title":"Prognostic factors in primary cutaneous anaplastic large cell lymphoma characterization of clinical subset with worse outcome","volume":"145","author":"Woo","year":"2009","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.04.081_bib21","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jaad.2015.12.053","article-title":"Cutaneous anaplastic large-cell lymphoma (ALCL): a comparative clinical feature and survival outcome analysis of 52 cases according to primary tumor site","volume":"74","author":"Lee","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2021.04.081_bib22","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/archdermatol.2009.280","article-title":"Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma","volume":"145","author":"Benner","year":"2009","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.04.081_bib23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"Modern\u00a0radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the international lymphoma radiation oncology group","volume":"92","author":"Specht","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.jaad.2021.04.081_bib24","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/bjd.16501","article-title":"Evaluation of treatment results in multifocal primary cutaneous anaplastic large cell lymphoma: report of the Dutch Cutaneous Lymphoma Group","volume":"179","author":"Melchers","year":"2018","journal-title":"Br J Dermatol"},{"issue":"suppl 5","key":"10.1016\/j.jaad.2021.04.081_bib25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/annonc\/mdq183","article-title":"Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Willemze","year":"2010","journal-title":"Ann Oncol"},{"issue":"10094","key":"10.1016\/j.jaad.2021.04.081_bib27","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jaad.2021.04.081_bib28","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1346-8138.2010.01150.x","article-title":"Primary cutaneous anaplastic large cell lymphoma with leg involvement: a case report and review of 11 cases","volume":"38","author":"Sugaya","year":"2011","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.04.081_bib29","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1067\/mjd.2001.117519","article-title":"Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and\u00a0bexarotene therapy","volume":"45","author":"French","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.04.081_bib30","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1111\/j.1365-2230.2008.03182.x","article-title":"Primary cutaneous CD30+ anaplastic large-cell lymphoma with generalized skin involvement and involvement of one peripheral lymph node, successfully treated with low-dose oral etoposide","volume":"34","author":"Yamane","year":"2009","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2021.04.081_bib31","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1080\/10428190903045385","article-title":"Sustained response of primary cutaneous CD30 positive anaplastic large cell lymphoma to bexarotene and photopheresis","volume":"50","author":"Sheehy","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.jaad.2021.04.081_bib32","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/ijd.13340","article-title":"Long-term follow-up and management of small and medium-sized CD4(+) T cell lymphoma and CD8(+) lymphoid proliferations of acral sites: a multicenter experience","volume":"55","author":"Virmani","year":"2016","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.04.081_bib33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/cup.12633","article-title":"Indolent CD8-positive lymphoid proliferation of acral sites: three further cases of a rare entity and an update on a unique patient","volume":"43","author":"Kluk","year":"2016","journal-title":"J Cutan Pathol"},{"issue":"20","key":"10.1016\/j.jaad.2021.04.081_bib34","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jaad.2021.04.081_bib35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.12788\/j.sder.2018.006","article-title":"Primary cutaneous CD4+ small\/medium T-cell lymphoproliferative disorder-clinical and histopathologic features, differential diagnosis, and treatment","volume":"37","author":"Gru","year":"2018","journal-title":"Semin Cutan Med Surg"},{"issue":"2","key":"10.1016\/j.jaad.2021.04.081_bib36","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group study of 83 cases","volume":"111","author":"Willemze","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jaad.2021.04.081_bib37","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jaad.2018.05.1243","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: clinical features, therapeutic approach, and outcome in a case series of 16 patients","volume":"79","author":"L\u00f3pez-Lerma","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"suppl 2","key":"10.1016\/j.jaad.2021.04.081_bib38","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0190-9622(03)00746-1","article-title":"Subcutaneous panniculitic T-cell lymphoma in children: response to combination therapy with cyclosporine and chemotherapy","volume":"50","author":"Shani-Adir","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.04.081_bib39","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/10428190601078456","article-title":"Cyclosporin in subcutaneous panniculitis-like T-cell lymphoma","volume":"48","author":"Rojnuckarin","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.jaad.2021.04.081_bib40","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0190-9622(97)80005-9","article-title":"Subcutaneous T-cell lymphoma treated with systemic chemotherapy, autologous stem cell support, and limb amputation","volume":"37","author":"Haycox","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.04.081_bib41","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2340\/00015555-2543","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: immunosuppressive drugs induce better response than polychemotherapy","volume":"97","author":"Michonneau","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2021.04.081_bib42","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjd.13053","article-title":"Systemic corticosteroids for subcutaneous panniculitis-like T-cell lymphoma","volume":"171","author":"Guenova","year":"2014","journal-title":"Br J Dermatol"},{"issue":"5 Suppl 1","key":"10.1016\/j.jaad.2021.04.081_bib43","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.jaad.2004.05.042","article-title":"High-dose chemotherapy with autologous blood stem cell transplantation for aggressive subcutaneous panniculitis-like T-cell lymphoma","volume":"52","author":"Alaibac","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.04.081_bib44","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0190-9622(96)90077-8","article-title":"Subcutaneous T-cell lymphoma with associated hemophagocytic syndrome and terminal leukemic transformation","volume":"34","author":"Romero","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.04.081_bib45","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/ejh.12439","article-title":"Gamma-delta t-cell lymphomas","volume":"94","author":"Foppoli","year":"2015","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.jaad.2021.04.081_bib46","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2002-05-1597","article-title":"Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma","volume":"101","author":"Toro","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jaad.2021.04.081_bib47","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40487-016-0026-y","article-title":"Cutaneous CD8+ cytotoxic T-cell lymphoma infiltrates: clinicopathological correlation and outcome of 35 cases","volume":"4","author":"Wobser","year":"2016","journal-title":"Oncol Ther"},{"issue":"5","key":"10.1016\/j.jaad.2021.04.081_bib48","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/modpathol.2016.240","article-title":"Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas","volume":"30","author":"Guitart","year":"2017","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.jaad.2021.04.081_bib49","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jaad.2011.07.043","article-title":"Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma: proposed diagnostic criteria and therapeutic evaluation","volume":"67","author":"Nofal","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.04.081_bib50","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.clml.2017.11.004","article-title":"Transplantation in the treatment of primary cutaneous aggressive epidermotropic cytotoxic CD8-positive T-cell lymphoma","volume":"18","author":"Cyrenne","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.jaad.2021.04.081_bib51","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jaad.2021.04.081_bib52","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jaad.2021.04.081_bib53","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jaad.2021.04.081_bib54","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00277-014-2188-8","article-title":"Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single-institution study of 105 Chinese patients","volume":"94","author":"Xu","year":"2015","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.jaad.2021.04.081_bib55","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","article-title":"Clinicopathologic characteristics of angioimmunoblastic t-cell lymphoma: analysis of the international peripheral T-cell lymphoma project","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jaad.2021.04.081_bib56","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2016-09-692541","article-title":"Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma","volume":"129","author":"Lunning","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jaad.2021.04.081_bib57","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1200\/JOP.18.00511","article-title":"Practical treatment approach for angioimmunoblastic T-cell lymphoma","volume":"15","author":"Moskowitz","year":"2019","journal-title":"J Oncol Pract"},{"issue":"9","key":"10.1016\/j.jaad.2021.04.081_bib58","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood-2016-08-692566","article-title":"Peripheral T-cell lymphoma, not otherwise specified","volume":"129","author":"Broccoli","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jaad.2021.04.081_bib59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.12788\/j.sder.2018.015","article-title":"NK\/T-cell lymphoma, nasal type, \u03b3\u03b4 T-cell lymphoma, and CD8-positive epidermotropic T-cell lymphoma-clinical and histopathologic features, differential diagnosis, and treatment","volume":"37","author":"Geller","year":"2018","journal-title":"Semin Cutan Med Surg"},{"issue":"12","key":"10.1016\/j.jaad.2021.04.081_bib60","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1111\/j.1349-7006.2009.01319.x","article-title":"Extranodal NK\/T-cell lymphoma, nasal type: new staging system and treatment strategies","volume":"100","author":"Kim","year":"2009","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.jaad.2021.04.081_bib61","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1200\/JCO.2005.04.1384","article-title":"Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jaad.2021.04.081_bib62","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/annonc\/mdh268","article-title":"CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature","volume":"15","author":"Bekkenk","year":"2004","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.jaad.2021.04.081_bib63","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1182\/blood-2005-05-2056","article-title":"Local tumor invasiveness is more predictive of survival than international prognostic index in stage I-E\/IIE extranodal NK\/T-cell lymphoma, nasal type","volume":"106","author":"Kim","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jaad.2021.04.081_bib64","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1038\/s41375-020-0740-1","article-title":"A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group","volume":"34","author":"Hong","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jaad.2021.04.081_bib65","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jamaoncol.2016.5094","article-title":"Association of improved locoregional control with prolonged survival in early-stage extranodal nasal-type natural killer\/T-cell lymphoma","volume":"3","author":"Yang","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.jaad.2021.04.081_bib66","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/bmt.2014.65","article-title":"Allogeneic haematopoietic SCT for natural killer\/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group","volume":"49","author":"Tse","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jaad.2021.04.081_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-016-0271-4","article-title":"L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia","volume":"9","author":"Jung","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"17","key":"10.1016\/j.jaad.2021.04.081_bib68","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing L-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jaad.2021.04.081_bib69","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2021.04.081_bib70","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fped.2018.00417","article-title":"Overview of EBV-associated T\/NK-cell lymphoproliferative diseases","volume":"6","author":"Kimura","year":"2019","journal-title":"Front Pediatr"},{"issue":"1","key":"10.1016\/j.jaad.2021.04.081_bib71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1346-8138.12328","article-title":"Skin manifestations of adult T-cell leukemia\/lymphoma: clinical, cytological and immunological features","volume":"41","author":"Tokura","year":"2014","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.04.081_bib72","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"issue":"24","key":"10.1016\/j.jaad.2021.04.081_bib73","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","article-title":"Treatment and survival among 1594 patients with ATL","volume":"126","author":"Katsuya","year":"2015","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.jaad.2021.04.081_bib74","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1182\/blood-2010-11-316794","article-title":"Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia\/lymphoma","volume":"117","author":"Sawada","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jaad.2021.04.081_bib75","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","article-title":"CCR4 mutations\u00a0associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"132","author":"Sakamoto","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jaad.2021.04.081_bib76","first-page":"1834","article-title":"A new classification of clinical stages of adult T-cell leukemia based on prognosis of the disease","volume":"8","author":"Shirono","year":"1994","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jaad.2021.04.081_bib77","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1200\/JCO.18.00501","article-title":"Revised adult T-cell leukemia-lymphoma international consensus meeting report","volume":"37","author":"Cook","year":"2019","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.jaad.2021.04.081_bib78","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia\/Lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.jaad.2021.04.081_bib79","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1182\/blood-2009-03-211821","article-title":"Phase 2\u00a0study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia\/lymphoma (ATL)","volume":"113","author":"Kchour","year":"2009","journal-title":"Blood"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221009270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221009270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:00:11Z","timestamp":1759273211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962221009270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0190962221009270"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.04.081","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary cutaneous T-cell lymphomas other than mycosis fungoides and S\u00e9zary syndrome. Part II: Prognosis and management","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.04.081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(21)02463-4","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}